Find clinical trials for Chronic Lymphocytic Leukemia in Birmingham, AL
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Chronic Lymphocytic Leukemia trials near Birmingham, AL, USA:
Study is a phase I study to determine the maximum tolerated dose of adding Loncastuximab Tesirine to Aclabrutinib in the treatment of chronic...
Phase 1
Birmingham, Alabama, United States
) and prednisone).The study includes patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic...
Phase 1, Phase 2
Birmingham, Alabama, United States and 76 other locations
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...
Phase 1, Phase 2
Birmingham, Alabama, United States and 79 other locations
with relapsed/ refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) in Part A and to furthe...
Phase 1
Birmingham, Alabama, United States and 31 other locations
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic...
Phase 1
Birmingham, Alabama, United States and 16 other locations
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation...
Phase 1, Phase 2
Birmingham, Alabama, United States and 118 other locations
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single ag...
Phase 1, Phase 2
Birmingham, Alabama, United States and 20 other locations
evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic...
Phase 1, Phase 2
Birmingham, Alabama, United States and 33 other locations
Clinical trials
Research sites
Resources
Legal